LinkedUp Bioscience

LinkedUp Bioscience (often referred to as LinkedUp Bio or Link-Use Biotech) is a biotechnology company that specializes in a proprietary antibody discovery engine. The company's platform integrates microfluidic single-cell B cell encapsulation with an in-house engineered yeast display and secretion system to efficiently identify and characterize therapeutic antibody candidates. Its lead program, LUB-001, is a pre-clinical antibody targeting a novel mechanism for the treatment of malignant melanoma and other solid tumors. Founded by US-trained scientists with significant experience at institutions like Peking Union Medical College, the company maintains operations in both Wakefield, Massachusetts, and Beijing, China. LinkedUp Bioscience aims to provide 'best-in-class' antibodies through its ability to capture the genetic makeup of the entire immune repertoire of multiple species.